These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38789477)

  • 1. Ganglioside SSEA-4 in Ewing sarcoma marks a tumor cell population with aggressive features and is a potential cell-surface immune target.
    Jamitzky S; Altvater B; Krekeler C; Hoen L; Brandes C; Ebbinghaus J; Richter L; Kosel L; Ochs L; Farwick N; Urban K; Kluge L; Bücker L; Görlich D; Johnston ICD; Pfeifer R; Hartmann W; Rossig C; Kailayangiri S
    Sci Rep; 2024 May; 14(1):11935. PubMed ID: 38789477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
    Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
    Kailayangiri S; Altvater B; Meltzer J; Pscherer S; Luecke A; Dierkes C; Titze U; Leuchte K; Landmeier S; Hotfilder M; Dirksen U; Hardes J; Gosheger G; Juergens H; Rossig C
    Br J Cancer; 2012 Mar; 106(6):1123-33. PubMed ID: 22374462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
    Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
    PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.
    Steinestel K; Trautmann M; Jansen EP; Dirksen U; Rehkämper J; Mikesch JH; Gerke JS; Orth MF; Sannino G; Arteaga MF; Rossig C; Wardelmann E; Grünewald TGP; Hartmann W
    Mol Oncol; 2020 Feb; 14(2):248-260. PubMed ID: 31811703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
    Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
    Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
    Issaq SH; Mendoza A; Kidner R; Rosales TI; Duveau DY; Heske CM; Rohde JM; Boxer MB; Thomas CJ; DeBerardinis RJ; Helman LJ
    Mol Cancer Ther; 2020 Jul; 19(7):1520-1529. PubMed ID: 32371575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
    Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
    Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically Engineered Mouse Model in Ewing Sarcoma.
    Tanaka M; Nakamura T
    Methods Mol Biol; 2021; 2226():183-189. PubMed ID: 33326102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
    Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
    Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
    He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
    Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma.
    Charville GW; Wang WL; Ingram DR; Roy A; Thomas D; Patel RM; Hornick JL; van de Rijn M; Lazar AJ
    Mod Pathol; 2017 Sep; 30(9):1312-1320. PubMed ID: 28643791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
    J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
    Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
    Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
    Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H
    Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma.
    Dallmayer M; Li J; Ohmura S; Alba Rubio R; Baldauf MC; Hölting TLB; Musa J; Knott MML; Stein S; Cidre-Aranaz F; Wehweck FS; Romero-Pérez L; Gerke JS; Orth MF; Marchetto A; Kirchner T; Bach H; Sannino G; Grünewald TGP
    Cell Death Dis; 2019 Feb; 10(2):116. PubMed ID: 30741933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.